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Abstract 
Aggregation of proteins is involved in many disorders. Besides amyloid fibrils, which mostly 
form in the brain, other kind of protein aggregates can lead, for example, to clots in the blood 
or floaters in the vitreous of the eye. This review is not only limited to amyloid diseases but 
aims at giving the reader a general overview on how nanomaterials can be employed to avoid 
and destroy protein aggregates of different nature.  Thanks to their recognized versatility, 
nanomaterials may offer attractive features against harmful protein aggregates. In addition to 
their known ability to interact with proteins, we also aim at providing a state-of-the-art on how 
stimuli-responsive nanomaterials can be employed to destroy aggregates. Despite promising 
and conceptually interesting strategies on how nanomaterials can lead to the destruction of 
protein aggregates and the prevention of their formation, it appears clearly that many efforts 
still remain, however, to demonstrate in vivo feasibility and safety to pave the way for clinically 
relevant therapies. 




Proteins are of crucial importance for the functioning of cells and organisms. They play a 
fundamental role in physiological processes and have a structural function in tissues. In some 
situations, the accumulation of misfolded proteins leads to insoluble and highly stable toxic 
aggregates, called amyloid fibrils. Currently 36 human amyloid proteins are known [1]. The 
aggregation of such amyloidogenic peptides is involved in many neurodegenerative disorders 
such as Parkinson (α-synuclein aggregates), Alzheimer (β-amyloid plaques), Huntington 
(polyglutamine aggregates) and Creutzfeldt-Jacob (amyloid deposits of the prion protein (PrP)). 
Aggregation of amyloidogenic peptides can also be found in type-II diabetes and cataracts [2–
5]. Besides amyloidogenic peptides, also other types of proteins can form aggregates according 
to various processes and induce different pathologies. For instance, the formation of thrombi, 
by a dysregulation of the hemostasis, also involves protein aggregation via polymerization of 
fibrin, thereby forming a network with aggregated platelets and coagulation factors [6]. 
Accumulation of proteins can also lead to more benign diseases. As an example, upon aging so 
named ‘floaters’ may occur in the vitreous due to the formation of collagen aggregates that cast 
shadows on the retina lowering visual acuity and contrast sensitivity [7]. Albeit not entirely 
constituted of proteins, kidney stones also involve proteins forming amalgams with organic or 
inorganic compounds [8]. All these types of aggregates might have a detrimental effect on 
human health and wellbeing. While extensive research is currently being carried out to get a 
better understanding of the pathophysiology of these diseases, many efforts still remain to be 
made to bring new therapeutic strategies. In addition to pharmacology and biology, the field of 




During the last decades, nano-sized materials have been extensively studied by the drug 
delivery community and pharmaceutical companies to improve the administration of drugs and 
biologics (especially for cancer therapy); examples include the commercialization of Doxil© 
(liposomal doxorubicin HCl) and Ambisome© (liposomal Amphotericin B) in the 90s and, 
more recently, Onpattro® (lipid nanoparticles carrying siRNA). Also for clinical diagnosis  
nano-sized materials are attractive, as for instance superparamagnetic iron oxide nanoparticles 
which are used as contrast agents for magnetic resonance imaging (MRI), in particular for 
cancer [9]. The combination of diagnosis and drug delivery has led to the emergence of a new 
field called ‘theranostics’ where nano-sized materials  play a central role as well [10].  
Extensive efforts in chemistry and physics have led to better understanding of the physico-
chemical properties of nano-sized materials which might further open the field for new 
biomedical applications. Due to their large surface and versatile properties (size, shape, 
surface), nano-sized materials may be very well suited as well for optimal recognition and 
interaction with peptide/protein aggregates. Polymeric, lipid-based or inorganic nanoparticles 
could be surface-functionalized with different ligands (antibodies, aptamers, small 
molecules…), which might improve their interaction with specific amino-acid sequences, thus 
inhibiting aggregation. This review will not focus on the pharmacological treatment of diseases 
related to protein aggregates,  but aims to shed light on the reported potential of ‘drug free’ 
nanomaterials in the management of protein aggregates through three strategic approaches, 
namely (i) preventing aggregate formation, (ii) clearing and (iii) destroying aggregates.  
 
2 Preventing the formation of peptide and protein aggregates with nanomaterials 
 A main mechanism for protein aggregation, often described as ‘fibrillation’, is the conversion 
of soluble monomers into large insoluble linear aggregates (also called amyloids). The 
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accumulation of such structures induces a loss of the protein function and high toxicity by 
disturbing intracellular transport, cellular functions and associated pathways. The formation of 
protein fibrils is a time-dependent process characterized by a sigmoidal curve consisting of a 
lag phase, an elongation phase and a final plateau regime [11]. As Figure 1A shows, the lag 
phase can be considered as a necessary ‘waiting phase’ or ‘activation time’ to activate nuclei 
and during which aggregation is not yet detectable. During this lag phase native protein 
monomers unfold. During the elongation phase monomers form oligomers that are elongating 
into beta-strand-stacked structures like protofibrils and/or fibrils until an equilibrium is reached 
(final plateau regime). It has been shown in vitro that the fibril formation occurs when the 
amount of monomers exceeds a ‘critical aggregation concentration’ following a mechanism 
very similar to the self-assembly of surfactants [12]. Many well-established methods can be 
employed to assess the fibrillation process. Several dyes like Thioflavin T (TfT) are commonly 
used because of their specific binding to cross-β-sheets structures resulting in enhanced 
fluorescence [13]. Other complementary techniques to study fibrillation are transmission 
electronic microscopy (TEM) imaging [14], atomic force microscopy (AFM) [15], circular 
dichroism spectroscopy (CD) [16] and X-ray diffraction [17]. 
Clearly, nucleation and fibril formation are largely dependent on pH, temperature and 
electrostatic interactions. The large surface to volume ratio of nanomaterials is an attractive 
feature which facilitates their binding to monomers and/or fibrils and prevents further assembly 
[15]. Nanomaterials can either prevent the association of monomers and/or disturb fibrils or 
plaques via hydrophobic interactions (Figure 1B). Moreover, they can also induce 
conformational changes of monomers thereby preventing the aggregation/fibrillation processes 
[19]. Below we discuss nanomaterials which have been reported to inhibit the formation of 




Figure 1. (A) Different phases of the formation of amyloid fibrils. This mechanism of fibril 
formation is found in most neurodegenerative diseases (adapted from [18]). (B) Interaction of 
nanoparticles with monomers and (mature) fibrils. The interaction with monomers may lead to 
a depletion of monomers in the bulk and retard the lag phase (dotted line in panel A). Through 
hydrophobic interactions, some nanomaterials can directly interact with mature fibrils (i.e. β 
sheets) and disassemble them. 
 
2.1  Aβ peptides in Alzheimer disease 
Alzheimer’s disease (AD) is the major cause of dementia in elderly persons with poor 
therapeutic possibilities and bad prognosis. The main pathological hallmark is the extracellular 
deposition of plaques in the brain which primarily consist of amyloid beta (Aβ) peptide. This 
peptide (consisting of 42 amino acids with a molecular weight around 4.5 kDa) can self-
assemble into filamentous β-sheet aggregates (amyloid aggregates) in solution [20]. This has 




Various types of nanomaterials have been studied to inhibit Aβ peptide aggregation in AD, 
based on their capacity to bind monomers and oligomers either with specific ligands or via 
hydrophobic interactions (Figure 2). Following the idea of capturing Aβ peptides, Cabaleiro-
Lago et al. described co-polymeric nanoparticles composed of N-isopropylacrylamide 
(NIPAM) and N-tert-butylacrylamide (BAM) [22]. A clear lengthening of the lag time and t1/2 
(half-time for fibrillation) was observed with ‘pure’ NIPAM nanoparticles while the presence 
of BAM in the copolymer required a higher concentration of nanoparticles to be efficient 
against the fibrillation process. The same team studied the effect of amino modified polystyrene 
nanoparticles on the Aβ fibrillation [23]. The authors revealed that this kind of particles either 
inhibited or accelerated the fibrillation, depending on the concentration of the nanoparticles in 
solution. They especially stressed the impact of the surface area of nanoparticles on the 
fibrillation process. For instance, when the concentration of particles is high, the amount of 
peptides remaining in the bulk lowers, which slows down the fibrillation rate (Figure 2A). 
However, when the concentration of particles is low, fibrillation can still occur and even be 
promoted at the surface of the nanoparticles which acts as a catalyzer. Such in vitro observations 
are of importance as they show that for AD treatment, a strong control over the concentration 
of nanoparticles in the brain would be required. In this regard, understanding the 
pharmacokinetics and controlling the bio-distribution of injected nanomaterials would be 
highly challenging and of high importance. Moreover, there is no evidence for specificity 
towards Aβ peptides and these nanomaterials may interact with other biological targets in vivo, 
further compromising their efficacy. 
Mahmoudi et al. further explored the effect of nanoparticles on fibrillation in a more complex 
medium. They observed that various types of nanoparticles (silica nanoparticles, COOH-
terminated polystyrene nanoparticles and multi-walled carbon nanotubes) accelerate the rate of 
Aβ fibril formation [24]. The authors tried to functionalize the nanoparticles by incubating them 
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with plasma proteins. They subsequently washed the nanoparticles to remove the loosely bound 
proteins, keeping the ‘hard corona’ i.e. the strongly bound proteins. Indeed it is now well known 
that after systemic administration, bare nanoparticles abundantly interact with blood proteins 
and get covered by a protein corona whose nature and composition varies according to the 
surface properties of the nanoparticles [25,26]. Interestingly, the authors showed that the 
presence of a protein corona on their nanoparticles could inhibit the fibrillation process, while 
bare (i.e. uncoated nanoparticles) accelerated surface-mediated fibrillation (Figure 2B). They 
explained that the protein corona creates a shell around the nanoparticles which reduces the 
access of Aβ peptides to the particles thus slowing down the formation of fibrils, unlike naked 
nanoparticles on which the Aβ peptides can attach and initiate fibrillation. However, in the 
conclusion of this study the authors remained careful regarding the benefits of this observation 
in vivo since it is known that Aβ oligomers are more toxic than mature Aβ fibrils and considered 
as being involved in the pathogenesis of Alzheimer disease [27]. 
The example above shows that the surface of nanomaterials plays a crucial role in the inhibition 
of the fibrillation of Aβ peptides. As surface properties of nanomaterials can be tuned, this 
might allow to control the aggregation kinetics. Though, also the mobility of Aβ peptides on 
the material surface itself can affect the fibrillation process (Figure 2C). When the diffusion of 
Aβ peptides on the surface is high, they can concentrate which initiates fibrillation. This is 
especially the case on smooth surfaces. Tuning the surface roughness might thus allow to 
control, to a certain extent, the fibrillation process. This was illustrated by Shezad et al. who 
showed for various polymer coatings and microparticles (using single molecule tracking, 
atomic force microscopy and TfT fluorescence) that rough surfaces present obstacles which 




In addition to polymeric nanoparticles, the potential of other types of nanomaterials to inhibit 
Aβ peptide fibrillation has been studied as well. Cadmium telluride quantum dots (CdTe QDs) 
functionalized with N-acetyl-L-cysteine were shown to be effective in inhibiting amyloid 
fibrillation at very low concentration (1-10 nM) and at any stage (monomers, oligomers and 
fibrils) [29]. In later reports also graphene QDs [30] and graphene oxides (GO) [31,32] were 
shown to inhibit Aβ peptide fibrillation. Nevertheless, these experiments were only performed 
in vitro. 
Molecular chaperones (like heat shock proteins, apoE, clusterin) play a critical role in cell 
homeostasis, repairing and maintaining the functional conformation of proteins [33]. They were 
also described as having a protective role against neurodegenerative diseases [34,35]. Through 
their ability to bind exposed hydrophobic regions of denatured or unfolded proteins, chaperones 
can detoxify cells from toxic aggregates and promote a return to a normal  protein homeostasis 
via proteasomal degradation. Taking inspiration from this, Huang et al. fabricated ‘artificial 
chaperones’ consisting of biocompatible, long circulating mixed shell polymeric micelles 
(MSPMs) with tunable surfaces (Figure 2D) [36]. These MSPMs were obtained by the self-
assembly of two amphipathic diblock copolymers, namely poly(e-caprolactone)-block-
poly(ethylene-oxide) (PCL-b-PEG) and poly(e-caprolactone)-block-poly(N-
isopropylacrylamide) (PCL-b-PNIPAM). At physiological temperature, PNIPAM chains 
collapse to form hydrophobic patches on the PCL core which facilitates the binding of Aβ 
hydrophobic monomers and oligomers (Figure 2D). Interestingly, the authors reported that 
MSPMs can both inhibit Aβ fibrillation and facilitate the degradation of MSPM-Aβ complexes 
by proteases. Also, curcumin (CUR, which has affinity for amyloid structures) has shown 
promising results in vitro and in an Alzheimer mouse model to target and prevent Aβ fibrillation 
[37]. Following these observations, gold nanoparticles functionalized with CUR were prepared. 
Since CUR is not water-soluble in its free form, authors decided to functionalize gold 
9 
 
nanoparticles with it. CUR-gold nanoparticles were able to both retard fibrillation and dissolve 
amyloid aggregates in vitro, as observed by TEM imaging and TFT fluorescence measurements 
(Figure 2E) [38]. Another example of artificial chaperones are nanogels (around 30 nm in size) 
composed of the polysaccharide pullulan and cholesterol, which have been shown to bind 
exposed hydrophobic regions of denatured proteins in vitro [39]; such nanogels were also able 
to incorporate and change the conformation of Aβ peptides [40]. 
Other interesting features of nanoparticles that can be exploited to prevent protein aggregation 
are their chiral properties. Enantiomeric nanoparticles, can be for instance used for 
enantioselective crystallization of racemic mixtures [41] – which is of high interest in the 
pharmaceutical field. In the context of amyloid formation, it has been demonstrated recently 
that α-helical intermediates are strongly involved in the fibrillation process and sensitive to 
chiral environments [42]. Therefore, chiral supramolecular complexes were investigated to 
inhibit Aβ aggregation [43]. It has been shown, for instance, that chiral penicillamine-modified 
selenium nanoparticles (Pen@Se NPs) could affect intracellular fibrillation of Aβ peptides 
(inside PC-12 cells) depending on their chiral properties [44]. D- Pen@Se NPs were shown to 
be effective to inhibit aggregation whereas L- Pen@Se NPs were not efficient. Interestingly, 
authors of this study reported notable ameliorations of mice cognition and memory 
impairments. Malishev et al. also applied this principle to Alzheimer’s disease using 
enantiomeric carbon dots (Cdots) either synthesized from L-lysine or D-lysine as carbon 
sources [45]. They showed that L-lys-Cdots had better interaction with monomers and pre-
fibrillar structures compared to D-lys-Cdots thereby affecting fibrillation and cytotoxicity. 
In the attractive studies discussed above, most of the experiments were only carried out in vitro. 
Mostly, no or rather poor data were provided on the capacity of such nanomaterials to cross the 
blood-brain-barrier (BBB), being very crucial to score the therapeutic potential. Liposomes, 
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being lipid-based nano-vesicles heavily used for drug delivery purposes, carrying CUR and 
functionalized with anti-transferrin antibodies as BBB targeting agents, were shown to prevent 
Aβ aggregation in vitro while they could label amyloid deposits in post-mortem brain tissues 
[46]. However, so far, these results have not been confirmed in vivo. In another report [47], 
liposomes functionalized with phosphatidic acid (PA) and a modified ApoE-derived peptide (a 
BBB targeting ligand) were shown to cross the BBB in an in-vitro BBB model. In vitro such 
liposomes also prevented Aβ peptide aggregation and disassembled preformed fibrils. Authors 
noticed a synergic effect between PA and ApoE since ‘mono-functionalized’ liposomes (i.e. 
PA-liposomes or ApoE-liposomes) did not show any effect. This is likely due to a preferential 
interaction of PA with cationic residues on the Aβ peptide and, conversely, an interaction of 
ApoE with anionic residues. In mice, biodistribution studies revealed higher radioactivity in the 
brain for radiolabeled mApoE-PA-liposomes compared to PA-liposomes suggesting a better 
crossing of the BBB. Though no information on memory recovery (an indication for treatment 





Figure 2. Aggregation of Aβ peptides can be influenced by different manners using 
nanoparticles. (A) The concentration of nanoparticles can impact Aβ peptide aggregation in 
different ways. At a low nanoparticle concentration, the density of monomers at the surface of 
nanoparticles increases, which catalyzes the fibrillation. In addition, the monomers remaining 
in the bulk also initiate the fibrillation (green curve). Overall this leads to an acceleration of the 
fibrillation compared to free monomers (without nanoparticles) in solution (black curve). At 
high nanoparticle concentration, less monomers remain in the solution which inhibits the 
fibrillation (red curve). (B) Schematic representation of the impact of a protein corona on the 
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fibrillation of Aβ peptides (adapted from [23]). (C) Impact of the surface properties of materials 
on the fibrillation process (adapted from [28]). (D) Polymeric micelles as artificial thermo-
responsive chaperones able to bind Aβ monomers and oligomers (adapted from [36]). (E) TfT 
fluorescence measurements reflecting the impact of CUR-functionalized gold nanoparticles on 
(i) fibrillation and (ii) dissolution of Aβ fibrils (with permission from [38]). 
2.2 α-synuclein in Parkinson disease   
In Parkinson and associated-diseases (synucleinopathies), α-synuclein, a 14 kDa protein whose 
role is still not elucidated, forms toxic amyloid fibrils in the midbrain in a similar manner as 
occurs in Alzheimer’s disease. Various types of dendrimers, being nano-sized branched 
polymers with a radially symmetric ‘tree-like’ structure (Figure 3Ai), were extensively studied 
to prevent the formation of fibrils involved in Parkinson disease. Dendrimers [48] are of high 
interest in drug delivery thanks to their versatility and capacity to be conjugated to different 
kinds of molecules (biologically active compounds or targeting ligands). In vitro, 
polyamidoamine (PAMAM) dendrimers of three different generations (G4, G5 and G6) could 
avoid the fibrillation of α-synuclein [49] through the amino groups at their surface which 
facilitate their interaction with α-synuclein. Also, these dendrimers showed a capacity to 
decompose fibrillary aggregates. Phosphorus [50,51] and carbosilane [52]  dendrimers similarly 
inhibited α -synuclein aggregation (in buffer solutions). Interestingly, Laumann et al. evaluated 
the capacity of polypropylenimine dendrimers, either terminated with urea (PPI-U) or 
methylthiourea (PPI-MTU), to disassemble intracellular α-synuclein aggregates [53]. Both 
types of dendrimers were able to solubilize aggregates present in human melanoma cells 




Curcumin has also a strong binding capacity to α-synuclein in the non-amyloid-β component 
region, preventing its aggregation [54]. Taebnia et al. developed amine-functionalized 
mesoporous silica nanoparticles (AAS-MSNPs) to encapsulate poorly-soluble drugs like CUR. 
The authors showed that α-synuclein can absorb on CUR present at the surface of the silica 
nanoparticles thereby inhibiting the fibrillation process [55]. More recently, spectacular results 
were obtained with graphene quantum dots (GQDs) able to prevent α-synuclein fibrillation and 
disassemble fibrils in vitro (Figure 3Bi and 3Bii). GQDs were shown to cross the BBB in vivo  
and bind mature α-synuclein fibrils injected in the hemisphere of mice, thereby disaggregating 





Figure 3. Several types of nanomaterials were reported to inhibit α-synuclein fibrillation. (A) 
(i) Schematic representation of the structure of a dendrimer. Some dendrimers (PPI-U and PPI-
MTU) were shown to disassemble α-synuclein aggregates in cells (ii) and in buffer (iii) (adapted 
from [53]). (B) (i) Schematic representation of the impact of GQDs on the fibrillation of α-
synuclein monomers and disaggregation of α-synuclein fibrils. (ii) TEM images of fibrils 
treated or not with GQDs as a function of time (up to 7 days). (iii) Representative 
phosphorylated α-synuclein (p- α-syn) immunostaining images in the striatum (STR) and 





2.3 Polyglutamine repeats in Huntington disease  
Huntington disease is an inherited disease involving the fibrillation of polyglutamine repeats 
into toxic intracellular aggregates. It is characterized by psychiatric, motor and cognitive 
alterations. Several sugars (maltose, glucose, sucrose, trehalose) can act as chemical chaperones 
in cells by stabilizing and restoring the folding of proteins [57] and can therefore be used to 
inhibit protein aggregation. For example, free trehalose has been shown to efficiently inhibit 
protein aggregation, not only in vitro but also in vivo with very promising results after oral 
administration in mice (Huntington disease model) [58]. It is assumed that trehalose can bind 
to expanded polyglutamines and stabilize amyloidogenic intermediates, therefore preventing 
further aggregation. 
It was recently observed that, compared to ‘molecular sugars’, sugar-terminated nanoparticles 
are much more effective in inhibiting protein aggregation [59]. Zwitterionic poly(trehalose) 
nanoparticles of 20-30 nm with an iron oxide core were prepared and tested in vitro and in vivo 
in mice (Huntington disease model). Such nanoparticles were designed to have improved 
intracellular uptake and a strong capacity to bind huntingtin by the presence of 20-800 trehalose 
molecules on their surface. They were shown to prevent aggregation of huntingtin in cultured 
HD150Q cells (Figure 4A), with a thousand times higher efficacy compared to free trehalose 
and to cross the BBB and block huntingtin aggregation in the brain of HD mice at micromolar 
concentrations (Figure 4B) [60]. In another study, the same authors reported on iron oxide 
nanoparticles carrying amino-acid based osmolytes, like glutamine and proline, at their surface. 
They observed again that, compared to molecular glutamine and proline, nanoparticles showed 
a significantly (1000 to 10 000 times) improved inhibition of the aggregation of the mutant 
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huntingtin protein [61]. Note that molecular trehalose has also been shown to reduce the 
aggregation of Aβ peptides [62] and islet amyloid polypeptides (IAPP) [63]. 
 
Figure 4. (A) Zwiterrionic poly(trehalose) nanoparticles were shown to prevent the aggregation 
of mutant GFP-tagged Huntingtin (in green) in cells. Nuclei were stained with DAPI (in blue). 
(B) Poly(trehalose) nanoparticles in a Huntington disease mouse model: nanoparticles flow 
through the blood, cross the blood brain barrier, enter neuronal cells in the brain, bind to 
polyglutamine containing mutant huntingtin (m-HTT) and block its aggregation. With 
permission from [60]. 
2.4 Islet amyloid polypeptides and insulin in type 2 diabetes 
As described above, amyloid plaques formation is involved in neurodegenerative diseases, 
though similar processes have been described in diabetes mellitus, especially in type 2 diabetes. 
Mature islet amyloid polypeptide (IAPP; 4 kDa), which contains 37 amino acids, can form 
insoluble amyloid fibrils (islet amyloids; β-sheet structures as occur in Alzheimer’s and 
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Parkinson disease). These aggregates are believed to be cytotoxic and to be correlated with the 
loss of β-cells in the pancreas and failure of islet transplants [64]. Cabaleiro-Lago et al. studied 
the effect of NIPAM:BAM nanoparticles on the amyloid formation by IAPP (in vitro). As they 
observed previously for Aβ peptides, ‘pure’ NIPAM nanoparticles showed the strongest 
inhibition of IAPP aggregation [65]. Generation 3 hydroxyl-terminated PAMAM dendrimers 
(PAMAM-OH) were also found to be effective in reducing the cytotoxicity of IAPP aggregates 
in NIT-1 and MIN6 cells and in mouse islets [66]. Moreover, dynamic light scattering and TEM 
revealed smaller aggregates while TfT measurements showed that PAMAM-OH dendrimers 
were able to stop the aggregation process up to 8 hours.  
Repeated administrations of insulin can lead to the formation of subcutaneous amyloid deposits 
at the injection site, leading to poor glycemic control and insulin resistance [67,68]. In literature, 
the inhibition of insulin fibrillation has been described, in a concentration-dependent manner 
with carbon dots [69]  and with silicon nanoparticles [70]. 
Using Fe3O4 magnetic nanoparticles coated with dextrans, Siposova et al. studied the influence 
of dextran chain length on insulin fibrillation and destruction of fibrils. While  destruction of 
insulin fibrils was observed with larger dextrans (70 kDa ), particles coated with smaller 
dextrans (15–20 kDa) showed higher inhibition against amyloid fibrillation (Figure 5A). The 
authors explained that the efficacy in inhibiting the fibrillation process by the smaller 
nanoparticles is likely due to their higher surface/volume ratio which favors the binding of 
monomers and thus lowers the concentration of free insulin in the bulk [71]. With larger 
particles, authors explain that many side-chain interactions with β-sheets structures highly 
contribute to their destruction 
While a common strategy is to prevent the fibrillation and/or destroy existing aggregates, 
changing the morphology of fibrils with the aim to reduce their toxicity is another original 
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approach. Using poly(2-hydroxyethyl acrylate) (PHEA) star polymers, Pilkington et al. 
succeeded in forming aggregates with a new morphology that they named “stelliform amyloids” 
as studied by atomistic molecular simulations (Figure 5B). The authors revealed an interesting 
correlation between PHEA stars mediated aggregation and a reduction of IAPP-mediated 
toxicity in pancreatic cells and islets [72]. 
 
Figure 5. (A) Schematic representation of  dextran coated nanoparticles either inhibiting insulin 
amyloid aggregation or destroying the aggregates (adapted from [71]). (B)  Star polymers can 
induce the formation of islet amyloid polypeptide (IAPP) aggregates with a new morphology 
which are less toxic for pancreatic cells and islets (with permission from [72]). 
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2.5 Collagen fibrillation 
Type I collagen is the most abundant protein in connective tissues. Self-assembly of collagen 
molecules into triple helixes is a crucial biological phenomenon to ensure the cohesion and 
maintenance of tissues and organs. On the other hand, collagen fibrillation is also involved in 
several disorders such as for example heart diseases, thrombosis and restenosis. Impacting 
collagen fibril formation is of high interest to reduce fibrosis. In fact, several attempts to block 
type I collagen self-assembly using monoclonal antibodies have been reported in the context of 
fibrosis inhibition [73,74] but only few examples involving nanomaterials are described. Based 
on the structure and constitutive amino acid sequence of collagen, Anand et al. designed AuNPs 
functionalized with hydroxyproline that are able to specifically recognize a sequence in the 
structure of type I collagen (in vitro), leading to binding and suppression of collagen fibril 
formation which might pave the way for reducing tissue fibrosis [75]. Wilson et al. showed that 
different effects could be observed on collagen fibrillation in vitro as a function of the charge 
of nanoparticles coated with polyelectrolytes. While negatively charged gold nanorods 
accelerated the fibrillation, positively charged particles could delay it [76]. 
2.6 Reflection on the surface characteristics for efficient inhibition of protein aggregation 
From all the examples described in the previous sections, we have listed several  types of surface 
that have shown an effect on protein aggregation (Table 1). Though this list is not exhaustive, 
we can conclude that nanoparticles with a rough and hydrophobic surface showed promising 
results. It appears that non-functionalized nanoparticles have interesting characteristics 
although they can be opsonized after intravenous injection. The functionalization of 
nanoparticles have also shown promising results via specific targeting of aggregates but does 
not seem to be indispensable. It is also worth noting that there are no or few examples of 
pegylated nanoparticles – highly likely because the steric hindrance does not allow an optimal 
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interaction with the aggregates – and also because the formation of a protein corona can 
facilitate the inhibition [24]. It seems, that each type of material can have a different effect 
depending on the nature of the aggregates. This is also highlighted in the case of chiral particles 
for which one enantiomer is more active than the other [44,45]. Similarly, some particles can 
slow down the aggregation of one type of aggregate whereas it accelerates it in other situations 
[77]. Also, it appears that there is no clear establishment of the role of the surface charge since 





Table 1. Summary of the different types of surface of nanomaterials commonly used to 
prevent protein aggregation. 
Surface features Type of materials Target proteins References 
Chiral • Carbon dots 
• Penicillamine-
modified selenium 
Aβ peptides  [44,45] 
Rough • Polystyrene 
nanoparticles 
Aβ peptides [28] 


























3 Clearing peptide monomers and removing protein aggregates with nanomaterials 
As discussed above, several studies report on various types of nanomaterials to inhibit plaque 
formation. It is highly important to keep in mind that most of these experiments were performed 
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in vitro. While the outcome of all this work is substantial and attractive, it remains (very) early 
stage. Indeed, most of the time, information on (i) the capacity for such nanomaterials to 
efficiently cross the BBB and (ii) their safety in vivo is not provided. Moreover, it is not 
completely sure that these nanomaterials will show similar effects if they are not acting in a 
‘pure system’ containing only one aggregating peptide or protein. This is why other strategies 
are explored to remove or disturb equilibria between peptides and aggregates. 
3.1 Disturbing the equilibrium between  fibrils and monomers   
In the case of Alzheimer’s disease, another strategy has emerged to prevent plaque formation 
and lies on the reduction of deposits in the brain by the clearance of circulating plasmatic Aβ 
monomers through a peripheral sink (Figure 6A) [79]. This approach thus focuses on the 
equilibrium between Aβ peptides in plasma and brain [80,81]: clearing peripheral Aβ 
monomers (i.e. by liver degradation) will disturb the equilibrium and lower the amount of Aβ 
monomers in the brain without the need for nanoparticles to cross the BBB, which is a very 
strong advantage of this approach. 
Following this concept, Carradori et al. designed biodegradable PEGylated nanoparticles 
composed of poly[hexadecyl cyanoacrylate-co-methoxypoly(ethylene glycol) cyanoacrylate], 
being well studied for drug delivery purposes [82], functionalized with anti Aβ peptide 
monoclonal antibodies. In the blood of mice, such nanoparticles were able to bind circulating 
Aβ peptides which were subsequently cleared from the circulation through common elimination 
pathways, reducing Aβ peptide aggregation in the brain. Spectacularly, this led to a significant 
memory recovery in mice without the need to reach the central nervous system [83].  In another 
report, liposomes functionalized with a modified human ApoE-derived peptide and 
phosphatidic acid were shown to be able to clear Aβ peptides in an in vitro BBB transwell 
model consisting of an apical (blood) and basolateral (brain) compartment separated by a 
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monolayer of brain microvascular endothelial cells. Such liposomes could also increase the 
concentration of Aβ monomers in plasma after injection in mice [84]. 
Knowing that apolipoprotein E3-reconstituted high density lipoprotein (ApoE3-rHDL) exhibits 
high affinity for Aβ monomers and oligomers, Song et al. proposed to accelerate their clearance 
using biomimetic ApoE3-rHDL nanoparticles prepared by self-assembly between DMPC 
vesicles and lipid-free Apo3 protein. The authors showed that such particles could facilitate 
liver and glial degradation of bound monomers. In vivo, intravenously-injected ApoE3-rHDL 
nanoparticles were shown to cross the BBB and to reduce amyloid deposition via Aβ 
degradation in the glial cells and rescue memory in mice [85].  
Recently, a ‘self-destructive nanosweeper’, consisting of a chitosan core functionalized with 
two peptides (KLVFF able to bind Aβ  peptides and Beclin1 able to induce autophagy) has been 
reported. As illustrated in Figure 6B, such particles carrying the Aβ monomers can be 
internalized in cells and trigger autophagy for their own destruction and clearance, thus 
allowing depletion of the Aβ monomers [86]. This autophagy-mediated destruction of 
nanosweepers  was shown to lower the amount of Aβ peptides in the brain.  As a result,  memory 
could be rescued in mice which was attributed to less amyloid deposits in the brain. 
Nevertheless, the authors explain they needed to use cyclosporine (a BBB permeability 
enhancer) to study the effect of the intravenously injected nanosweepers in the brain. Only 2% 
of the total injected dose of nanosweepers was found in the brain of mice after sacrifice. This 
again underlines the difficulty of reaching the brain after systemic injection,  a clear limitation 





Figure 6. (A) Clearance of circulating plasmatic Aβ monomers using functionalized 
nanoparticles (NPs). Thanks to the elimination of the nanoparticles carrying Aβ monomers, a 
’sink’ effect is induced that displaces the equilibrium and contributes to the destruction of 
amyloid deposits in the brain. (B) Schematic representation of the concept of ‘nanosweepers’. 
This type of nanoparticle can recognize and bind Aβ monomers and trigger autophagy of 
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hyppocampal neurons after being internalized by cells. This creates a local depletion of Aβ 
monomers which eventually alters amyloid plaques in the brain (adapted from [86]). 
3.2 Magnetic removal of fibrils 
Early diagnosis of neurodegenerative diseases is the key for efficient prevention of lethal 
complications. Visualizing plaques with imaging agents (like gadolinium), to determine their 
location, could give precious information for early diagnosis [87] . Also, the detection of low 
concentrations of Aβ peptides in plasma is of high interest [88].  
For the  purpose of fluorescence and magnetic imaging of Aβ40 fibrils, Skaat et al. designed 
fluorescent maghemite nanoparticles  (γ-Fe2O3 NPs). Although such nanoparticles did not have 
any effect on the fibrillation kinetics, they allowed fluorescence staining of fibrils in vitro and 
easy removal from the aqueous phase with a simple magnet [89]. Though these results were 
original, magnetic removal of plaques from the brain remains of course highly questionable 
since no information is given regarding the (i) capacity of γ-Fe2O3 NPs to cross the BBB and 
(ii) the capacity of magnets to move plaques in the brain.  
4 Destroying peptide and protein aggregates with stimuli-responsive nanomaterials 
4.1 Electromagnetic irradiation and magnetic heating 
If the use of microwaves in combination with gold nanoparticles has been intensively explored 
for cancer hyperthermia and to improve the effect of chemotherapeutics [90], it can also be 
harnessed to destroy protein aggregates. Bastus et al. proposed to apply this strategy to 
Alzheimer’s disease to locally destroy Aβ deposits using gold nanoparticles functionalized with 
a targeting peptide (AuNP-cys-PEP). When exposed to a weak microwave field, AuNPs could 
heat up and destroy the aggregates. Upon 8 hours of irradiation with a weak microwave field, 
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Aβ deposits were dissolved in vitro without any bulk heating (Figure 7A) [91]. However, such 
a long exposure time cannot be envisaged for in vivo applications. 
The same strategy was employed by the same group on prefibrillar intermediate amyloidogenic 
aggregates (PIAA) which are known to assemble and form fibrils [92]. After incubating PIAA 
with AuNP-CLPFFD and irradiation with weak microwaves, no fibril formation could be 
observed, whereas without irradiation (i.e only with AuNP-CLPFFD), fibril formation 
occurred. 
Besides microwaves, also alternating magnetic fields combined with inorganic nanoparticles 
(like iron oxide particles) have been widely studied (and clinically used [93]) in cancer therapy 
(hyperthermia) [94]. In the context of protein aggregation, a few studies have explored this 
strategy using magnetic particles to destroy blood clots. Indeed, fast destruction of blood clots 
is a major challenge in medicine to achieve reperfusion of affected tissues after acute stroke. 
Tissue plasminogen activator (tPA) is one of the most used medication for the treatment of 
acute ischemic stroke. However, tPA treatment is often associated with intracranial hemorrhage 
[95]. To reduce undesired effects, nanoconstructs were prepared by immobilizing tPA on 20 
nm iron oxide nanocubes surrounded by albumin (Figure 7Bi). The mixture of tPA and albumin 
strongly stabilizes the nanoconstructs and prevents leakage of tPA, thus limiting unwanted side 
effects. By direct contact with the fibrin network, an improved dissolution of blood clots in 
vitro could be observed (100-fold faster dissolution as compared with free tPA) which authors 
attributed to a specific interaction between albumin and the fibrin network (Figure 7Bii). When 
exposed to an alternating magnetic field, such iron oxide based nanoconstructs could further 




Figure 7. (A) Left: electron microscopy image of gold nanoparticles (functionalized with 
targeting ligands) bound to Aβ1–42 aggregates. Right: electron microscopy image after 
irradiating the aggregates for 8 hours with a weak microwave magnetic field. Bars are 500 nm. 
With permission from [91]. (B) (i) tPA nanoconstructs (tPA-NCs) were shown to improve 
dissolution rate of blood clots (ii) which could be further improved when an alternate magnetic 
field was applied (adapted from [96]). 
4.2 Ultrasound and microbubbles 
Also ultrasound (US) energy and microbubbles (MBs; typically composed of a lipid or 
polymeric shell and a gaseous core) are attractive to destroy blood clots. Bursting such MBs 
upon applying ultrasound might provide sufficient mechanical energy to release encapsulated 
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drugs and break nearby blood clots. The combined use of MBs, ultrasound and tPA has indeed 
been studied in vitro and in vivo (rabbits) in a stroke model [97]. The authors showed that tPA 
doses can be reduced (up to 5-fold) to achieve significant clot loss in the presence of MB and 
ultrasounds. In vivo, the combination of MBs and tPA showed a significant decrease in infarct 
volume compared to controls. As far as we know, the use of microbubbles and ultrasound to 
break pathological protein aggregates (other than blood clots) has not been explored. 
4.3 Light 
Carbon-based nanomaterials are known to absorb near infrared light making them good 
candidates for photothermal therapies and destruction of protein aggregates. Yang and 
coworkers reported that graphene oxide nanosheets modified with thioflavine S (a dye that 
specifically binds to Aβ fibrils), upon exposure to near infrared (NIR) light, could dissociate 
fibrils in buffer and ex vivo in cerebrospinal fluid collected from mice through hyperthermic 
effects [98]. 
An interesting feature of metallic nanoparticles -especially noble metals- is their plasmonic 
properties and their capacity to absorb light at different wavelengths as a function of their size 
and shape. For instance, (negatively charged) 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
(DMPC) coated gold nanorods were shown to easily bind to the cationic amyloid sequence of 
Aβ peptides. On the one hand, such particles could inhibit amyloid fibrillation when added 
during the early stage of fibrillation. On the other hand, when these particles were added to 
mature fibrils and NIR laser light was applied for some minutes, a thermal dissociation of the 
fibrils could be achieved [99]. In another work, Triulzi et al. showed that a targeted 
photothermal ablation of amyloid plaques was possible using a preferential interaction between 
amyloid deposits and AuNPs functionalized with truncated Aβ peptides. Exposing amyloid 
aggregates in vitro with continuous laser light resulted in their photothermal ablation whereas 
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non functionalized particles did not bind the aggregates and therefore could not ablate them 
after light exposure [100]. Interestingly, the ablation of plaques could only be observed at the 
site of irradiation with minimal thermal effects in surrounding areas. 
It is known that AuNPs quickly heat up upon pulsed-laser light exposure, being attractive for 
photothermal therapies [101]. Also, under appropriate conditions, irradiating AuNPs with 
pulsed-laser light results in  the formation of  vapor nanobubbles (VNBs) due to  the evaporation 
of water which surrounds the gold nanoparticles. The burst of  such VNBs provides  mechanical 
energy which is sufficient to, for example, transfect cells with different cargos by transient pore 
formation in the plasma membrane [102]. Though they did not mention the formation of VNBs, 
Lin et al. showed that femtosecond pulsed laser illumination of AuNPs allows to destroy  
amyloid plaques in vitro. Thanks to their plasmon properties, the illumination of gold nanorods 
(800 nm) with a femtosecond laser can induce their fragmentation (named explosion by the 
authors) which provides sufficient mechanical force to fragment Aβ fibrils as observed by 
atomic force microscopy [103] (Figure 8A).  
The very local increase in temperature may be also of interest to control the structure and 
folding/unfolding of proteins; indeed, Kang et al. reported that in the immediate adjacent 
environment of AuNPs illuminated with a pulsed-laser, proteins can be denatured [104]. This 
interesting feature could find applications to treat diseases involving protein unfolding and 
aggregation. Though such strategies may be promising, one must keep in mind that (i) 
surrounding tissues may be heated as well, leading to unwanted effects and (ii) the 
fragmentation of fibrils may generate toxic fragments.  
All previous examples concern in vitro research and are difficult to evaluate in clinical 
experiments, especially due to the limited penetration of light in the body. As the eye is easily 
accessible to both light and advanced materials, our group has an interest in photothermal 
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treatment of ophthalmological diseases. Recently we explored to which extent VNB may be 
suitable to destroy vitreous opacities (also named ‘floaters’) [105] (Figure 8B). Eye floaters 
are protein aggregates mostly composed of a mixture of different types of collagen that are 
present in the vitreous [106,107]. We synthesized hyaluronic acid-coated AuNPs which 
exhibited high mobility in vitreous and bound collagen fibers to selectively generate VNBs on 
eye floaters and were able to ‘photo-ablate’ them allowing a preservation of the surrounding 
vitreous. However, in vivo toxicity studies still need to be performed. 
 
Figure 8. (A) After illumination with a femtosecond laser amyloid fibrils can be broken thanks 
to the explosion of gold nanorods. Atomic force microscopy (AFM) observations showed fibrils 
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were destroyed (adapted from [103]). (B) Top: principle of photo-ablation of vitreous opacities. 
After intravitreal injection, gold nanoparticles can diffuse and bind floaters. Pulsed-laser 
illumination of the vitreous opacities induced the generation of vapor nanobubbles which will 
burst and destroy the opacities. Bottom: dark field microscopy image of a floater obtained after 
vitrectomy of a patient treated with 10 nm HA-AuNPs respectively before and after illumination 
with a nanosecond laser ( 3 pulses of  800 µJ (adapted from[105]). 
5 Toxicity and biodistribution of nanomaterials 
In this part, we will discuss and reflect on toxicity concerns and distribution of nanomaterials 
used to avoid or destroy protein aggregates. Since the toxicity of materials is not the scope of 
this review, we will restrict this part to materials that showed the most relevant results in the 
context of protein aggregation. 
We have shown that several types of nanomaterials could efficiently contribute to avoid or 
destroy protein aggregates alone or in combination with stimuli. Important, however, is to stress 
on the toxicity and safety profile of such materials considering that biocompatibility and 
biodegradability are two major requirements for further clinical use. Whereas some examples 
highlighted in this review refer to liposomes – for which safety profile and toxicity have been 
already shown for many years – the safe use of inorganic nanoparticles is still not clearly 
established [108]. This is especially the case with gold nanoparticles whose toxicity and 
biodistribution differ according to their size, shape and surface charges. For example, smaller 
gold nanoparticles (< 5 nm) have been reported to be toxic binding to DNA strands [109]. This 
is of major importance, especially with the use of pulsed lasers as we have previously discussed 
for the treatment of vitreous opacities or amyloid plaques (see section 4.3). It is indeed known 
that after such laser irradiations, gold nanoparticles can fragment [110] and therefore have 
reduced size which can be harmful – a strong control and further investigations on this process 
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are therefore required before any clinical use. Quantum and carbon dots also appeared to be 
attractive, especially as we have seen that they could avoid the formation of α-synuclein 
aggregates in the brain and show nice results in mice [56]. Compared to IONPs, that are already 
approved for clinical use [111], no clear toxicity profile was established with graphene quantum 
dots or carbon dots. Extensive efforts therefore remain for a better understanding of the 
biodistribution and the toxicity of such materials which can be modulated according to their 
surface properties (cite). 
Various polymers have shown interesting results. One of the first work reporting on the use of 
polymer nanoparticles and protein aggregation from Cabaleiro-Lago et al. [22], was with 
NIPAM nanoparticles. This type of polymer nanoparticles was then studied several times in 
different context of protein aggregation and for drug delivery purposes. This polymer has been 
shown to be safe in vitro in several cell lines [112] and showed relative toxicity in others 
depending on the preparation methods [113]. In rabbits, its use as an ocular bioadhesive did not 
show toxicity [114]. However, it appears that some studies on biodegradation and 
biodistribution  are still lacking and that other polymers have supplanted this one for drug 
delivery applications. Therefore, studying the anti-aggregation properties of polymers with 
known toxicity or approved for human use will be convenient. 
It is now well-established in the drug delivery community and beyond that PEGylated 
nanoparticles allow a prolongation of residence in the bloodstream through decreased 
interactions with blood proteins. Important, however, would be to find a balance between blood 
circulation time (which will increase the likelihood of the particles to bind the aggregates) and 
the interaction of such nanomaterials with aggregates after intravenous injections. Indeed, one 
can assume that PEGylated particles – due to steric hindrance – have none or poor interaction 
with amyloids. This also explains why there are no or poor examples of pegylated nanoparticles 
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that have been studied for the inhibition of fibrillation. Other strategies that allow a prolongation 
of time in the blood stream without affecting binding to protein aggregates are therefore needed. 
For instance, studying different shapes of nanoparticles in terms of inhibition of aggregation 
could be interesting – knowing that different shapes have also been reported to increase the 
circulation time in blood [115]. 
 
Conclusions 
We reviewed the main nanotechnology based concepts and materials under investigation to 
prevent and fight the aggregation of proteins in a pathological context. If other strategies 
involving compounds of different nature have shown promising results against protein 
aggregation (e.g.: polyphenols [116], tetracyclines [117] or specific antibodies [118]), 
nanomaterials are still intriguing especially through their capacity to adsorb proteins on their 
surface to allow a control on their aggregation.  Besides, their surface can be tuned specifically 
for this purpose, which is a clear advantage over bulk materials. However, it appears clearly 
that there is an important lack of animal studies as, indeed, most concepts are so far only 
investigated in vitro or ex vivo. To further explore nanomaterial-based approaches to prevent 
protein aggregation and/or destroy aggregates in the context of neurodegenerative diseases, 
designing nanomaterials able to access the central nervous system still remains a huge 
challenge. The use of external stimuli to interfere with protein aggregation/aggregates, like light 
or ultrasound, also raises the challenge of reaching the aggregates in the human body with those 
stimuli, which especially in the case of light poses problems due to limited tissue penetration 
(with the exception of aggregates in the eye). There is a strong necessity to be able to image 
and detect protein aggregates in the body; those expectations could be met, for example, by 
innovative (nano)theranostic approaches. Important to note as well is that in several studies it 
34 
 
appeared that amyloid intermediates are even more toxic than mature fibrils or plaques 
[119,120]. One could thus assume that maintaining a high amount of monomers and/or 
oligomers (either by blocking the fibrillation or disassembling aggregates) could induce high 
toxicity as well. This phenomenon must be taken into consideration, especially in the case of 
Alzheimer’s disease. Also, further studies are needed to get better insights in the fate of protein 
aggregate fragments which arise after the application of stimuli (light, heat, ultrasound). 
Especially to know is whether such fragments may form fibrils/aggregates again i.e. whether 
the destruction is reversible or not. Moreover, there is a clear lack of information regarding the 
nature of the fragments – as there is no indications on whether there are in the molecular state 
or consist in smaller aggregates. There is a clear need for further studies to clarify this point 
which for the moment remains a major issue. Clearly, the reviewed literature demonstrates that 
there is still a long way to go to provide promising nanotechnology based strategies to prevent 
in vivo protein aggregation or destroy protein aggregates. A better understanding of both the 
pathogenesis as well as the biophysical behavior of nanomaterials in complex biological 
environments remains highly needed to make next steps towards efficient and original 
therapies. Indeed, most of the nanoparticles reported to inhibit protein aggregation are studied 
in buffers which often occults important physiological aspects such as stability in biofluids (e.g. 
blood), biocompatibility and pharmacokinetics. It is clear that the problems inherent in the 
control of protein aggregation are finally close to those of the field of drug delivery - and more 
generally to the one of nanomedicine - with a strong need to adapt materials to human 
physiology. 
Funding 
This research did not receive any specific grant from funding agencies in the public, 
commercial, or not-for-profit sectors. 
35 
 
Declarations of interest: none. 
Authors biography 
 
Félix Sauvage received his pharmacy degree in 2013 at the University of Rouen, France. The 
same year, he obtained his Master’s degree in Pharmaceutical Technology and 
Biopharmaceutics at University Paris-Saclay and a fellowship from the French Ministry of 
Higher Education and Research. He joined the Institut-Galien Paris-Sud (University Paris-
Saclay, France) for a PhD. In 2017, Félix Sauvage joined the Laboratory of General 
Biochemistry and Physical Pharmacy at Ghent University as a postdoctoral research scientist. 







Katrien Remaut graduated as a Pharmacist at Ghent University in 2001. She then started her 
PhD in the Lab of General Biochemistry and Physical Pharmacy under guidance of Prof. De 
Smedt and Prof. Demeester. In 2007, she received the title of Doctor in Pharmaceutical Sciences 
and continued research work as a postdoctoral fellow of the Research Foundation Flanders. In 
2013, Katrien was elected as member of the Young Academy in Flanders. She was appointed 
tenure track professor at the Lab General Biochemistry and Physical Pharmacy of Ghent 
University in 2014. Her research focuses on ocular gene delivery and peritoneal carcinomatosis. 
 
Kevin Braeckmans obtained a Master’s Degree in Physics at Ghent University in 1999. Next, 
he joined the Laboratory of General Biochemistry and Physical Pharmacy to perform research 
on advanced optical microscopy methods for pharmaceutical applications. In 2004, he started 
his post-doctoral fellowship and was appointed Professor at Ghent University in 2008 where he 
is currently leading the Bio-Photonics Research Group in close collaboration with the Ghent 
Research Group on Nanomedicines. In 2015 he was awarded an ERC Consolidator Grant. His 
37 
 
research focuses on the study of biological barriers of functional nanomaterials by advanced 
microscopy techniques and light-triggered drug delivery. 
 
Stefaan C. De Smedt studied pharmacy and graduated from Ghent University in 1995. He 
joined the pharmaceutical development group of Janssen Research Foundation (1995–97). 
Following post-doctoral research at the Departments of Pharmacy in Ghent and Utrecht he 
became Professor in Physical Pharmacy and Biopharmacy at Ghent University in 1999 where 
he founded the Ghent Research Group on Nanomedicines. He served as dean of his faculty from 
2010–2014. Currently he is a Specially Appointed Professor of Nanjing Forestry University. In 
2015, he became Editor of JCR for the region Europe-Middle East & Africa. His research is 









[1] J.D. Sipe, M.D. Benson, J.N. Buxbaum, S.-I. Ikeda, G. Merlini, M.J.M. Saraiva, P. 
Westermark, Amyloid fibril proteins and amyloidosis: chemical identification and 
clinical classification International Society of Amyloidosis 2016 Nomenclature 
Guidelines, Amyloid Int. J. Exp. Clin. Investig. Off. J. Int. Soc. Amyloidosis. 23 (2016) 
209–213. doi:10.1080/13506129.2016.1257986. 
[2] M.S. Hipp, S.-H. Park, F.U. Hartl, Proteostasis impairment in protein-misfolding and -
aggregation diseases, Trends Cell Biol. 24 (2014) 506–514. 
doi:10.1016/j.tcb.2014.05.003. 
[3] A.M. Blokhuis, E.J.N. Groen, M. Koppers, L.H. van den Berg, R.J. Pasterkamp, Protein 
aggregation in amyotrophic lateral sclerosis, Acta Neuropathol. (Berl.). 125 (2013) 777–
794. doi:10.1007/s00401-013-1125-6. 
[4] K.L. Moreau, J.A. King, Protein misfolding and aggregation in cataract disease and 
prospects for prevention, Trends Mol. Med. 18 (2012) 273–282. 
doi:10.1016/j.molmed.2012.03.005. 
[5] S. Meehan, Y. Berry, B. Luisi, C.M. Dobson, J.A. Carver, C.E. MacPhee, Amyloid 
Fibril Formation by Lens Crystallin Proteins and Its Implications for Cataract Formation, 
J. Biol. Chem. 279 (2004) 3413–3419. doi:10.1074/jbc.M308203200. 
[6] M.F.B.G. Gebbink, B. Bouma, C. Maas, B.N. Bouma, Physiological responses to protein 
aggregates: Fibrinolysis, coagulation and inflammation (new roles for old factors), FEBS 
Lett. 583 (2009) 2691–2699. doi:10.1016/j.febslet.2009.06.013. 
[7] R. Milston, M.C. Madigan, J. Sebag, Vitreous floaters: Etiology, diagnostics, and 
management, Surv. Ophthalmol. 61 (2016) 211–227. 
doi:10.1016/j.survophthal.2015.11.008. 
[8] O.W. Moe, Kidney stones: pathophysiology and medical management, The Lancet. 367 
(2006) 333–344. doi:10.1016/S0140-6736(06)68071-9. 
[9] I. Brigger, C. Dubernet, P. Couvreur, Nanoparticles in cancer therapy and diagnosis, 
Adv. Drug Deliv. Rev. 64 (2012) 24–36. doi:10.1016/j.addr.2012.09.006. 
[10] S.S. Kelkar, T.M. Reineke, Theranostics: Combining Imaging and Therapy, Bioconjug. 
Chem. 22 (2011) 1879–1903. doi:10.1021/bc200151q. 
[11] P. Arosio, T.P. J. Knowles, S. Linse, On the lag phase in amyloid fibril formation, Phys. 
Chem. Chem. Phys. 17 (2015) 7606–7618. doi:10.1039/C4CP05563B. 
[12] M. Novo, S. Freire, W. Al-Soufi, Critical aggregation concentration for the formation of 
early Amyloid-β (1–42) oligomers, Sci. Rep. 8 (2018). doi:10.1038/s41598-018-19961-
3. 
[13] H. LeVine, Thioflavine T interaction with synthetic Alzheimer’s disease beta-amyloid 




[14] S.L. Gras, L.J. Waddington, K.N. Goldie, Transmission electron microscopy of amyloid 
fibrils, Methods Mol. Biol. Clifton NJ. 752 (2011) 197–214. doi:10.1007/978-1-60327-
223-0_13. 
[15] C. Goldsbury, J. Kistler, U. Aebi, T. Arvinte, G.J.S. Cooper, Watching amyloid fibrils 
grow by time-lapse atomic force microscopy11Edited by W. Baumeister, J. Mol. Biol. 
285 (1999) 33–39. doi:10.1006/jmbi.1998.2299. 
[16] C.J. Barrow, A. Yasuda, P.T.M. Kenny, M.G. Zagorski, Solution conformations and 
aggregational properties of synthetic amyloid β-peptides of Alzheimer’s disease: 
Analysis of circular dichroism spectra, J. Mol. Biol. 225 (1992) 1075–1093. 
doi:10.1016/0022-2836(92)90106-T. 
[17] S.B. Malinchik, H. Inouye, K.E. Szumowski, D.A. Kirschner, Structural Analysis of 
Alzheimer’s β(1–40) Amyloid: Protofilament Assembly of Tubular Fibrils, Biophys. J. 
74 (1998) 537–545. doi:10.1016/S0006-3495(98)77812-9. 
[18] M. Zaman, E. Ahmad, A. Qadeer, G. Rabbani, R.H. Khan, Nanoparticles in relation to 
peptide and protein aggregation, Int. J. Nanomedicine. 9 (2014) 899–912. 
doi:10.2147/IJN.S54171. 
[19] N.K. Ramesh, S. Sudhakar, E. Mani, Modeling of the Inhibitory Effect of Nanoparticles 
on Amyloid β Fibrillation, Langmuir. 34 (2018) 4004–4012. 
doi:10.1021/acs.langmuir.8b00388. 
[20] J.D. Harper, P.T. Lansbury, Models of amyloid seeding in Alzheimer’s disease and 
scrapie: mechanistic truths and physiological consequences of the time-dependent 
solubility of amyloid proteins, Annu. Rev. Biochem. 66 (1997) 385–407. 
doi:10.1146/annurev.biochem.66.1.385. 
[21] L. Fei, S. Perrett, Effect of Nanoparticles on Protein Folding and Fibrillogenesis, Int. J. 
Mol. Sci. 10 (2009) 646–655. doi:10.3390/ijms10020646. 
[22] C. Cabaleiro-Lago, F. Quinlan-Pluck, I. Lynch, S. Lindman, A.M. Minogue, E. Thulin, 
D.M. Walsh, K.A. Dawson, S. Linse, Inhibition of Amyloid β Protein Fibrillation by 
Polymeric Nanoparticles, J. Am. Chem. Soc. 130 (2008) 15437–15443. 
doi:10.1021/ja8041806. 
[23] C. Cabaleiro-Lago, F. Quinlan-Pluck, I. Lynch, K.A. Dawson, S. Linse, Dual Effect of 
Amino Modified Polystyrene Nanoparticles on Amyloid β Protein Fibrillation, ACS 
Chem. Neurosci. 1 (2010) 279–287. doi:10.1021/cn900027u. 
[24] M. Mahmoudi, M.P. Monopoli, M. Rezaei, I. Lynch, F. Bertoli, J.J. McManus, K.A. 
Dawson, The Protein Corona Mediates the Impact of Nanomaterials and Slows Amyloid 
Beta Fibrillation, ChemBioChem. 14 (2013) 568–572. doi:10.1002/cbic.201300007. 
[25] T. Cedervall, I. Lynch, S. Lindman, T. Berggård, E. Thulin, H. Nilsson, K.A. Dawson, 
S. Linse, Understanding the nanoparticle–protein corona using methods to quantify 
exchange rates and affinities of proteins for nanoparticles, Proc. Natl. Acad. Sci. 104 
(2007) 2050–2055. doi:10.1073/pnas.0608582104. 
40 
 
[26] M. Lundqvist, J. Stigler, G. Elia, I. Lynch, T. Cedervall, K.A. Dawson, Nanoparticle size 
and surface properties determine the protein corona with possible implications for 
biological impacts, Proc. Natl. Acad. Sci. 105 (2008) 14265–14270. 
doi:10.1073/pnas.0805135105. 
[27] D.M. Walsh, I. Klyubin, J.V. Fadeeva, M.J. Rowan, D.J. Selkoe, Amyloid-β oligomers: 
their production, toxicity and therapeutic inhibition, Biochem. Soc. Trans. 30 (2002) 
552–557. doi:10.1042/bst0300552. 
[28] K. Shezad, K. Zhang, M. Hussain, H. Dong, C. He, X. Gong, X. Xie, J. Zhu, L. Shen, 
Surface Roughness Modulates Diffusion and Fibrillation of Amyloid-β Peptide, 
Langmuir. 32 (2016) 8238–8244. doi:10.1021/acs.langmuir.6b01756. 
[29] L. Xiao, D. Zhao, W.-H. Chan, M.M.F. Choi, H.-W. Li, Inhibition of beta 1–40 amyloid 
fibrillation with N-acetyl-l-cysteine capped quantum dots, Biomaterials. 31 (2010) 91–
98. doi:10.1016/j.biomaterials.2009.09.014. 
[30] Y. Liu, L.-P. Xu, W. Dai, H. Dong, Y. Wen, X. Zhang, Graphene quantum dots for the 
inhibition of β amyloid aggregation, Nanoscale. 7 (2015) 19060–19065. 
doi:10.1039/c5nr06282a. 
[31] Q. Li, L. Liu, S. Zhang, M. Xu, X. Wang, C. Wang, F. Besenbacher, M. Dong, 
Modulating Aβ33–42 Peptide Assembly by Graphene Oxide, Chem. – Eur. J. 20 (2014) 
7236–7240. doi:10.1002/chem.201402022. 
[32] M. Mahmoudi, O. Akhavan, M. Ghavami, F. Rezaee, S.M.A. Ghiasi, Graphene oxide 
strongly inhibits amyloid beta fibrillation, Nanoscale. 4 (2012) 7322–7325. 
doi:10.1039/C2NR31657A. 
[33] F. Sauvage, S. Messaoudi, E. Fattal, G. Barratt, J. Vergnaud-Gauduchon, Heat shock 
proteins and cancer: How can nanomedicine be harnessed?, J. Controlled Release. 248 
(2017) 133–143. doi:10.1016/j.jconrel.2017.01.013. 
[34] P.J. Muchowski, J.L. Wacker, Modulation of neurodegeneration by molecular 
chaperones, Nat. Rev. Neurosci. 6 (2005) 11–22. doi:10.1038/nrn1587. 
[35] A.B. Meriin, M.Y. Sherman, Role of molecular chaperones in neurodegenerative 
disorders, Int. J. Hyperth. Off. J. Eur. Soc. Hyperthermic Oncol. North Am. Hyperth. 
Group. 21 (2005) 403–419. doi:10.1080/02656730500041871. 
[36] F. Huang, J. Wang, A. Qu, L. Shen, J. Liu, J. Liu, Z. Zhang, Y. An, L. Shi, Maintenance 
of amyloid β peptide homeostasis by artificial chaperones based on mixed-shell 
polymeric micelles, Angew. Chem. Int. Ed Engl. 53 (2014) 8985–8990. 
doi:10.1002/anie.201400735. 
[37] M. Garcia‐Alloza, L.A. Borrelli, A. Rozkalne, B.T. Hyman, B.J. Bacskai, Curcumin 
labels amyloid pathology in vivo, disrupts existing plaques, and partially restores 




[38] S. Palmal, A.R. Maity, B.K. Singh, S. Basu, N.R. Jana, N.R. Jana, Inhibition of Amyloid 
Fibril Growth and Dissolution of Amyloid Fibrils by Curcumin–Gold Nanoparticles, 
Chem. – Eur. J. 20 (2014) 6184–6191. doi:10.1002/chem.201400079. 
[39] Y. Nomura, Y. Sasaki, M. Takagi, T. Narita, Y. Aoyama, K. Akiyoshi, 
Thermoresponsive controlled association of protein with a dynamic nanogel of 
hydrophobized polysaccharide and cyclodextrin: heat shock protein-like activity of 
artificial molecular chaperone, Biomacromolecules. 6 (2005) 447–452. 
doi:10.1021/bm049501t. 
[40] Ikeda Keisuke, Okada Takuma, Sawada Shin-ichi, Akiyoshi Kazunari, Matsuzaki 
Katsumi, Inhibition of the formation of amyloid β‐protein fibrils using biocompatible 
nanogels as artificial chaperones, FEBS Lett. 580 (2006) 6587–6595. 
doi:10.1016/j.febslet.2006.11.009. 
[41] L.C. Preiss, L. Werber, V. Fischer, S. Hanif, K. Landfester, Y. Mastai, R. Muñoz‐Espí, 
Amino-Acid-Based Chiral Nanoparticles for Enantioselective Crystallization, Adv. 
Mater. 27 (2015) 2728–2732. doi:10.1002/adma.201405531. 
[42] C.A. De Carufel, N. Quittot, P.T. Nguyen, S. Bourgault, Delineating the Role of Helical 
Intermediates in Natively Unfolded Polypeptide Amyloid Assembly and Cytotoxicity, 
Angew. Chem. Int. Ed. 54 (2015) 14383–14387. doi:10.1002/anie.201507092. 
[43] M. Li, S.E. Howson, K. Dong, N. Gao, J. Ren, P. Scott, X. Qu, Chiral Metallohelical 
Complexes Enantioselectively Target Amyloid β for Treating Alzheimer’s Disease, J. 
Am. Chem. Soc. 136 (2014) 11655–11663. doi:10.1021/ja502789e. 
[44] D. Sun, W. Zhang, Q. Yu, X. Chen, M. Xu, Y. Zhou, J. Liu, Chiral penicillamine-
modified selenium nanoparticles enantioselectively inhibit metal-induced amyloid β 
aggregation for treating Alzheimer’s disease, J. Colloid Interface Sci. 505 (2017) 1001–
1010. doi:10.1016/j.jcis.2017.06.083. 
[45] R. Malishev, E. Arad, S.K. Bhunia, S. Shaham-Niv, S. Kolusheva, E. Gazit, R. Jelinek, 
Chiral modulation of amyloid beta fibrillation and cytotoxicity by enantiomeric carbon 
dots, Chem. Commun. 54 (2018) 7762–7765. doi:10.1039/C8CC03235A. 
[46] S. Mourtas, A.N. Lazar, E. Markoutsa, C. Duyckaerts, S.G. Antimisiaris, 
Multifunctional nanoliposomes with curcumin–lipid derivative and brain targeting 
functionality with potential applications for Alzheimer disease, Eur. J. Med. Chem. 80 
(2014) 175–183. doi:10.1016/j.ejmech.2014.04.050. 
[47] L. Bana, S. Minniti, E. Salvati, S. Sesana, V. Zambelli, A. Cagnotto, A. Orlando, E. 
Cazzaniga, R. Zwart, W. Scheper, M. Masserini, F. Re, Liposomes bi-functionalized 
with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and 
cross the blood-brain-barrier: implications for therapy of Alzheimer disease, 
Nanomedicine Nanotechnol. Biol. Med. 10 (2014) 1583–1590. 
doi:10.1016/j.nano.2013.12.001. 
[48] E. Abbasi, S.F. Aval, A. Akbarzadeh, M. Milani, H.T. Nasrabadi, S.W. Joo, Y. 
Hanifehpour, K. Nejati-Koshki, R. Pashaei-Asl, Dendrimers: synthesis, applications, and 
properties, Nanoscale Res. Lett. 9 (2014) 247. doi:10.1186/1556-276X-9-247. 
42 
 
[49] A. Rekas, V. Lo, G.E. Gadd, R. Cappai, S.I. Yun, PAMAM dendrimers as potential 
agents against fibrillation of alpha-synuclein, a Parkinson’s disease-related protein, 
Macromol. Biosci. 9 (2009) 230–238. doi:10.1002/mabi.200800242. 
[50] K. Milowska, J. Grochowina, N. Katir, A. El Kadib, J.-P. Majoral, M. Bryszewska, T. 
Gabryelak, Viologen-Phosphorus Dendrimers Inhibit α-Synuclein Fibrillation, Mol. 
Pharm. 10 (2013) 1131–1137. doi:10.1021/mp300636h. 
[51] K. Milowska, T. Gabryelak, M. Bryszewska, A.-M. Caminade, J.-P. Majoral, 
Phosphorus-containing dendrimers against α-synuclein fibril formation, Int. J. Biol. 
Macromol. 50 (2012) 1138–1143. doi:10.1016/j.ijbiomac.2012.02.003. 
[52] K. Milowska, A. Szwed, M. Mutrynowska, R. Gomez-Ramirez, F.J. de la Mata, T. 
Gabryelak, M. Bryszewska, Carbosilane dendrimers inhibit α-synuclein fibrillation and 
prevent cells from rotenone-induced damage, Int. J. Pharm. 484 (2015) 268–275. 
doi:10.1016/j.ijpharm.2015.02.066. 
[53] K. Laumann, U. Boas, H.M. Larsen, P.M.H. Heegaard, A.-L. Bergström, Urea and 
Thiourea Modified Polypropyleneimine Dendrimers Clear Intracellular α-Synuclein 
Aggregates in a Human Cell Line, Biomacromolecules. 16 (2015) 116–124. 
doi:10.1021/bm501244m. 
[54] B. Ahmad, L.J. Lapidus, Curcumin Prevents Aggregation in α-Synuclein by Increasing 
Reconfiguration Rate, J. Biol. Chem. 287 (2012) 9193–9199. 
doi:10.1074/jbc.M111.325548. 
[55] N. Taebnia, D. Morshedi, S. Yaghmaei, F. Aliakbari, F. Rahimi, A. Arpanaei, 
Curcumin-Loaded Amine-Functionalized Mesoporous Silica Nanoparticles Inhibit α-
Synuclein Fibrillation and Reduce Its Cytotoxicity-Associated Effects, Langmuir. 32 
(2016) 13394–13402. doi:10.1021/acs.langmuir.6b02935. 
[56] D. Kim, J.M. Yoo, H. Hwang, J. Lee, S.H. Lee, S.P. Yun, M.J. Park, M. Lee, S. Choi, 
S.H. Kwon, S. Lee, S.-H. Kwon, S. Kim, Y.J. Park, M. Kinoshita, Y.-H. Lee, S. Shin, 
S.R. Paik, S.J. Lee, S. Lee, B.H. Hong, H.S. Ko, Graphene quantum dots prevent α-
synucleinopathy in Parkinson’s disease, Nat. Nanotechnol. (2018) 1. 
doi:10.1038/s41565-018-0179-y. 
[57] T. Arakawa, D. Ejima, Y. Kita, K. Tsumoto, Small molecule pharmacological 
chaperones: From thermodynamic stabilization to pharmaceutical drugs, Biochim. 
Biophys. Acta. 1764 (2006) 1677–1687. doi:10.1016/j.bbapap.2006.08.012. 
[58] M. Tanaka, Y. Machida, S. Niu, T. Ikeda, N.R. Jana, H. Doi, M. Kurosawa, M. Nekooki, 
N. Nukina, Trehalose alleviates polyglutamine-mediated pathology in a mouse model of 
Huntington disease, Nat. Med. 10 (2004) 148–154. doi:10.1038/nm985. 
[59] N. Pradhan, S. Shekhar, N.R. Jana, N.R. Jana, Sugar-Terminated Nanoparticle 
Chaperones Are 102–105 Times Better Than Molecular Sugars in Inhibiting Protein 
Aggregation and Reducing Amyloidogenic Cytotoxicity, ACS Appl. Mater. Interfaces. 9 
(2017) 10554–10566. doi:10.1021/acsami.7b01886. 
[60] K. Debnath, N. Pradhan, B.K. Singh, N.R. Jana, N.R. Jana, Poly(trehalose) 
Nanoparticles Prevent Amyloid Aggregation and Suppress Polyglutamine Aggregation 
43 
 
in a Huntington’s Disease Model Mouse, ACS Appl. Mater. Interfaces. 9 (2017) 24126–
24139. doi:10.1021/acsami.7b06510. 
[61] N. Pradhan, N.R. Jana, N.R. Jana, Inhibition of Protein Aggregation by Iron Oxide 
Nanoparticles Conjugated with Glutamine- and Proline-Based Osmolytes, ACS Appl. 
Nano Mater. 1 (2018) 1094–1103. doi:10.1021/acsanm.7b00245. 
[62] R. Liu, H. Barkhordarian, S. Emadi, C.B. Park, M.R. Sierks, Trehalose differentially 
inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42, Neurobiol. Dis. 20 
(2005) 74–81. doi:10.1016/j.nbd.2005.02.003. 
[63] C.-H. Chen, T. Yao, Q. Zhang, Y.-M. He, L.-H. Xu, M. Zheng, G.-R. Zhou, Y. Zhang, 
H.-J. Yang, P. Zhou, Influence of trehalose on human islet amyloid polypeptide 
fibrillation and aggregation, RSC Adv. 6 (2016) 15240–15246. 
doi:10.1039/C5RA27689F. 
[64] P. Westermark, A. Andersson, G.T. Westermark, Islet Amyloid Polypeptide, Islet 
Amyloid, and Diabetes Mellitus, Physiol. Rev. 91 (2011) 795–826. 
doi:10.1152/physrev.00042.2009. 
[65] C. Cabaleiro-Lago, I. Lynch, K.A. Dawson, S. Linse, Inhibition of IAPP and 
IAPP(20−29) Fibrillation by Polymeric Nanoparticles, Langmuir. 26 (2010) 3453–3461. 
doi:10.1021/la902980d. 
[66] E.N. Gurzov, B. Wang, E.H. Pilkington, P. Chen, A. Kakinen, W.J. Stanley, S.A. 
Litwak, E.G. Hanssen, T.P. Davis, F. Ding, P.C. Ke, Inhibition of hIAPP Amyloid 
Aggregation and Pancreatic β-Cell Toxicity by OH-Terminated PAMAM Dendrimer, 
Small. 12 (2016) 1615–1626. doi:10.1002/smll.201502317. 
[67] F.E. Dische, C. Wernstedt, G.T. Westermark, P. Westermark, M.B. Pepys, J.A. Rennie, 
S.G. Gilbey, P.J. Watkins, Insulin as an amyloid-fibril protein at sites of repeated insulin 
injections in a diabetic patient, Diabetologia. 31 (1988) 158–161. 
doi:10.1007/BF00276849. 
[68] N. Tanio, T. Nozaki, M. Matsusako, J. Starkey, K. Suzuki, Imaging characteristics of 
subcutaneous amyloid deposits in diabetic patients: the “insulin ball,” Skeletal Radiol. 
47 (2018) 85–92. doi:10.1007/s00256-017-2749-8. 
[69] S. Li, L. Wang, C.C. Chusuei, V.M. Suarez, P.L. Blackwelder, M. Micic, J. Orbulescu, 
R.M. Leblanc, Nontoxic Carbon Dots Potently Inhibit Human Insulin Fibrillation, Chem. 
Mater. 27 (2015) 1764–1771. doi:10.1021/cm504572b. 
[70] Y. Ma, R. Huang, W. Qi, R. Su, Z. He, Fluorescent silicon nanoparticles inhibit the 
amyloid fibrillation of insulin, J. Mater. Chem. B. 7 (2019) 1397–1403. 
doi:10.1039/C8TB02964D. 
[71] K. Siposova, K. Pospiskova, Z. Bednarikova, I. Safarik, M. Safarikova, M. 
Kubovcikova, P. Kopcansky, Z. Gazova, The molecular mass of dextran used to modify 
magnetite nanoparticles affects insulin amyloid aggregation, J. Magn. Magn. Mater. 427 
(2017) 48–53. doi:10.1016/j.jmmm.2016.10.083. 
44 
 
[72] E.H. Pilkington, M. Lai, X. Ge, W.J. Stanley, B. Wang, M. Wang, A. Kakinen, M.-A. 
Sani, M.R. Whittaker, E.N. Gurzov, F. Ding, J.F. Quinn, T.P. Davis, P.C. Ke, Star 
Polymers Reduce Islet Amyloid Polypeptide Toxicity via Accelerated Amyloid 
Aggregation, Biomacromolecules. 18 (2017) 4249–4260. 
doi:10.1021/acs.biomac.7b01301. 
[73] H.J. Chung, A. Steplewski, K.Y. Chung, J. Uitto, A. Fertala, Collagen Fibril Formation, 
J. Biol. Chem. 283 (2008) 25879–25886. doi:10.1074/jbc.M804272200. 
[74] A. Steplewski, A. Fertala, Inhibition of collagen fibril formation, Fibrogenesis Tissue 
Repair. 5 (2012) S29. doi:10.1186/1755-1536-5-S1-S29. 
[75] B.G. Anand, K. Dubey, D.S. Shekhawat, K.P. Prajapati, K. Kar, Strategically Designed 
Antifibrotic Gold Nanoparticles to Prevent Collagen Fibril Formation, Langmuir. 33 
(2017) 13252–13261. doi:10.1021/acs.langmuir.7b01504. 
[76] C.G. Wilson, P.N. Sisco, F.A. Gadala-Maria, C.J. Murphy, E.C. Goldsmith, 
Polyelectrolyte-coated gold nanorods and their interactions with type I collagen, 
Biomaterials. 30 (2009) 5639–5648. doi:10.1016/j.biomaterials.2009.07.011. 
[77] C. Cabaleiro-Lago, O. Szczepankiewicz, S. Linse, The Effect of Nanoparticles on 
Amyloid Aggregation Depends on the Protein Stability and Intrinsic Aggregation Rate, 
Langmuir. 28 (2012) 1852–1857. doi:10.1021/la203078w. 
[78] K. Dubey, B.G. Anand, R. Badhwar, G. Bagler, P.N. Navya, H.K. Daima, K. Kar, 
Tyrosine- and tryptophan-coated gold nanoparticles inhibit amyloid aggregation of 
insulin, Amino Acids. 47 (2015) 2551–2560. doi:10.1007/s00726-015-2046-6. 
[79] Y. Matsuoka, M. Saito, J. LaFrancois, M. Saito, K. Gaynor, V. Olm, L. Wang, E. Casey, 
Y. Lu, C. Shiratori, C. Lemere, K. Duff, Novel therapeutic approach for the treatment of 
Alzheimer’s disease by peripheral administration of agents with an affinity to beta-
amyloid, J. Neurosci. Off. J. Soc. Neurosci. 23 (2003) 29–33. 
[80] R.B. DeMattos, K.R. Bales, D.J. Cummins, J.-C. Dodart, S.M. Paul, D.M. Holtzman, 
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ 
burden in a mouse model of Alzheimer’s disease, Proc. Natl. Acad. Sci. U. S. A. 98 
(2001) 8850–8855. doi:10.1073/pnas.151261398. 
[81] R.B. DeMattos, K.R. Bales, D.J. Cummins, S.M. Paul, D.M. Holtzman, Brain to plasma 
amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of 
Alzheimer’s disease, Science. 295 (2002) 2264–2267. doi:10.1126/science.1067568. 
[82] J. Nicolas, P. Couvreur, Synthesis of poly(alkyl cyanoacrylate)-based colloidal 
nanomedicines, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1 (2009) 111–127. 
doi:10.1002/wnan.15. 
[83] D. Carradori, C. Balducci, F. Re, D. Brambilla, B. Le Droumaguet, O. Flores, A. 
Gaudin, S. Mura, G. Forloni, L. Ordoñez-Gutierrez, F. Wandosell, M. Masserini, P. 
Couvreur, J. Nicolas, K. Andrieux, Antibody-functionalized polymer nanoparticle 
leading to memory recovery in Alzheimer’s disease-like transgenic mouse model, 




[84] S. Mancini, S. Minniti, M. Gregori, G. Sancini, A. Cagnotto, P.-O. Couraud, L. 
Ordóñez-Gutiérrez, F. Wandosell, M. Salmona, F. Re, The hunt for brain Aβ oligomers 
by peripherally circulating multi-functional nanoparticles: Potential therapeutic approach 
for Alzheimer disease, Nanomedicine Nanotechnol. Biol. Med. 12 (2016) 43–52. 
doi:10.1016/j.nano.2015.09.003. 
[85] Q. Song, M. Huang, L. Yao, X. Wang, X. Gu, J. Chen, J. Chen, J. Huang, Q. Hu, T. 
Kang, Z. Rong, H. Qi, G. Zheng, H. Chen, X. Gao, Lipoprotein-Based Nanoparticles 
Rescue the Memory Loss of Mice with Alzheimer’s Disease by Accelerating the 
Clearance of Amyloid-Beta, ACS Nano. 8 (2014) 2345–2359. doi:10.1021/nn4058215. 
[86] Q. Luo, Y.-X. Lin, P.-P. Yang, Y. Wang, G.-B. Qi, Z.-Y. Qiao, B.-N. Li, K. Zhang, J.-P. 
Zhang, L. Wang, H. Wang, A self-destructive nanosweeper that captures and clears 
amyloid β-peptides, Nat. Commun. 9 (2018) 1802. doi:10.1038/s41467-018-04255-z. 
[87] G. Bort, S. Catoen, H. Borderies, A. Kebsi, S. Ballet, G. Louin, M. Port, C. Ferroud, 
Gadolinium-based contrast agents targeted to amyloid aggregates for the early diagnosis 
of Alzheimer’s disease by MRI, Eur. J. Med. Chem. 87 (2014) 843–861. 
doi:10.1016/j.ejmech.2014.10.016. 
[88] C.-C. Yang, S.-Y. Yang, J.-J. Chieh, H.-E. Horng, C.-Y. Hong, H.-C. Yang, K.H. Chen, 
B.Y. Shih, T.-F. Chen, M.-J. Chiu, Biofunctionalized Magnetic Nanoparticles for 
Specifically Detecting Biomarkers of Alzheimer’s Disease in Vitro, ACS Chem. 
Neurosci. 2 (2011) 500–505. doi:10.1021/cn200028j. 
[89] H. Skaat, S. Margel, Synthesis of fluorescent-maghemite nanoparticles as multimodal 
imaging agents for amyloid-β fibrils detection and removal by a magnetic field, 
Biochem. Biophys. Res. Commun. 386 (2009) 645–649. 
doi:10.1016/j.bbrc.2009.06.110. 
[90] F.H. Ghahremani, A. Sazgarnia, M.H. Bahreyni-Toosi, O. Rajabi, A. Aledavood, 
Efficacy of microwave hyperthermia and chemotherapy in the presence of gold 
nanoparticles: an in vitro study on osteosarcoma, Int. J. Hyperth. Off. J. Eur. Soc. 
Hyperthermic Oncol. North Am. Hyperth. Group. 27 (2011) 625–636. 
doi:10.3109/02656736.2011.587363. 
[91] N.G. Bastus, M.J. Kogan, R. Amigo, D. Grillo-Bosch, E. Araya, A. Turiel, A. Labarta, 
E. Giralt, V.F. Puntes, Gold nanoparticles for selective and remote heating of β-amyloid 
protein aggregates, Mater. Sci. Eng. C. 27 (2007) 1236–1240. 
doi:10.1016/j.msec.2006.08.003. 
[92] E. Araya, I. Olmedo, N.G. Bastus, S. Guerrero, V.F. Puntes, E. Giralt, M.J. Kogan, Gold 
Nanoparticles and Microwave Irradiation Inhibit Beta-Amyloid Amyloidogenesis, 
Nanoscale Res. Lett. 3 (2008) 435–443. doi:10.1007/s11671-008-9178-5. 
[93] N.V.S. Vallabani, S. Singh, Recent advances and future prospects of iron oxide 




[94] S. Laurent, S. Dutz, U.O. Häfeli, M. Mahmoudi, Magnetic fluid hyperthermia: Focus on 
superparamagnetic iron oxide nanoparticles, Adv. Colloid Interface Sci. 166 (2011) 8–
23. doi:10.1016/j.cis.2011.04.003. 
[95] M.G. Lansberg, V.N. Thijs, R. Bammer, S. Kemp, C.A.C. Wijman, M.P. Marks, G.W. 
Albers, DEFUSE Investigators, Risk factors of symptomatic intracerebral hemorrhage 
after tPA therapy for acute stroke, Stroke. 38 (2007) 2275–2278. 
doi:10.1161/STROKEAHA.106.480475. 
[96] E. Voros, M. Cho, M. Ramirez, A.L. Palange, E.D. Rosa, J. Key, Z. Garami, A.B. 
Lumsden, P. Decuzzi, TPA Immobilization on Iron Oxide Nanocubes and Localized 
Magnetic Hyperthermia Accelerate Blood Clot Lysis, Adv. Funct. Mater. 25 (2015) 
1709–1718. doi:10.1002/adfm.201404354. 
[97] A.T. Brown, R. Flores, E. Hamilton, P.K. Roberson, M.J. Borrelli, W.C. Culp, 
Microbubbles Improve Sonothrombolysis In Vitro and Decrease Hemorrhage In Vivo in 
a Rabbit Stroke Model, Invest. Radiol. 46 (2011). doi:10.1097/RLI.0b013e318200757a. 
[98] M. Li, X. Yang, J. Ren, K. Qu, X. Qu, Using Graphene Oxide High Near-Infrared 
Absorbance for Photothermal Treatment of Alzheimer’s Disease, Adv. Mater. 24 (2012) 
1722–1728. doi:10.1002/adma.201104864. 
[99] S. Sudhakar, P.B. Santhosh, E. Mani, Dual Role of Gold Nanorods: Inhibition and 
Dissolution of Aβ Fibrils Induced by Near IR Laser, ACS Chem. Neurosci. 8 (2017) 
2325–2334. doi:10.1021/acschemneuro.7b00238. 
[100] R.C. Triulzi, Q. Dai, J. Zou, R.M. Leblanc, Q. Gu, J. Orbulescu, Q. Huo, Photothermal 
ablation of amyloid aggregates by gold nanoparticles, Colloids Surf. B Biointerfaces. 63 
(2008) 200–208. doi:10.1016/j.colsurfb.2007.12.006. 
[101] X. Huang, P.K. Jain, I.H. El-Sayed, M.A. El-Sayed, Plasmonic photothermal therapy 
(PPTT) using gold nanoparticles, Lasers Med. Sci. 23 (2008) 217. doi:10.1007/s10103-
007-0470-x. 
[102] R. Xiong, K. Raemdonck, K. Peynshaert, I. Lentacker, I. De Cock, J. Demeester, S.C. 
De Smedt, A.G. Skirtach, K. Braeckmans, Comparison of Gold Nanoparticle Mediated 
Photoporation: Vapor Nanobubbles Outperform Direct Heating for Delivering 
Macromolecules in Live Cells, ACS Nano. 8 (2014) 6288–6296. 
doi:10.1021/nn5017742. 
[103] D. Lin, R. He, S. Li, Y. Xu, J. Wang, G. Wei, M. Ji, X. Yang, Highly Efficient 
Destruction of Amyloid-β Fibrils by Femtosecond Laser-Induced Nanoexplosion of 
Gold Nanorods, ACS Chem. Neurosci. 7 (2016) 1728–1736. 
doi:10.1021/acschemneuro.6b00244. 
[104] P. Kang, Z. Chen, S.O. Nielsen, K. Hoyt, S. D’Arcy, J.J. Gassensmith, Z. Qin, 
Molecular Hyperthermia: Spatiotemporal Protein Unfolding and Inactivation by 
Nanosecond Plasmonic Heating, Small Weinh. Bergstr. Ger. 13 (2017). 
doi:10.1002/smll.201700841. 
[105] F. Sauvage, J.C. Fraire, K. Remaut, J. Sebag, K. Peynshaert, M. Harrington, F.J. Van 
de velde, R. Xiong, M.-J. Tassignon, T. Brans, K. Braeckmans, S.C. De Smedt, Photo-
47 
 
Ablation of Human Vitreous Opacities by Light-Induced Vapor Nanobubbles, ACS 
Nano. (2019). doi:10.1021/acsnano.9b04050. 
[106] P.N. Bishop, D.F. Holmes, K.E. Kadler, D. McLeod, K.J. Bos, Age-Related Changes 
on the Surface of Vitreous Collagen Fibrils, Invest. Ophthalmol. Vis. Sci. 45 (2004) 
1041–1046. doi:10.1167/iovs.03-1017. 
[107] P.N. Bishop, Structural macromolecules and supramolecular organisation of the 
vitreous gel, Prog. Retin. Eye Res. 19 (2000) 323–344. 
[108] S.J. Soenen, P. Rivera-Gil, J.-M. Montenegro, W.J. Parak, S.C. De Smedt, K. 
Braeckmans, Cellular toxicity of inorganic nanoparticles: Common aspects and 
guidelines for improved nanotoxicity evaluation, Nano Today. 6 (2011) 446–465. 
doi:10.1016/j.nantod.2011.08.001. 
[109] P. Rivera Gil, D. Hühn, L.L. del Mercato, D. Sasse, W.J. Parak, Nanopharmacy: 
Inorganic nanoscale devices as vectors and active compounds, Pharmacol. Res. 62 
(2010) 115–125. doi:10.1016/j.phrs.2010.01.009. 
[110] A.R. Ziefuß, S. Reichenberger, C. Rehbock, I. Chakraborty, M. Gharib, W.J. Parak, S. 
Barcikowski, Laser Fragmentation of Colloidal Gold Nanoparticles with High-Intensity 
Nanosecond Pulses is Driven by a Single-Step Fragmentation Mechanism with a 
Defined Educt Particle-Size Threshold, J. Phys. Chem. C. 122 (2018) 22125–22136. 
doi:10.1021/acs.jpcc.8b04374. 
[111] A.C. Anselmo, S. Mitragotri, A Review of Clinical Translation of Inorganic 
Nanoparticles, AAPS J. 17 (2015) 1041–1054. doi:10.1208/s12248-015-9780-2. 
[112] P.C. Naha, K. Bhattacharya, T. Tenuta, K.A. Dawson, I. Lynch, A. Gracia, F.M. Lyng, 
H.J. Byrne, Intracellular localisation, geno- and cytotoxic response of polyN-
isopropylacrylamide (PNIPAM) nanoparticles to human keratinocyte (HaCaT) and colon 
cells (SW 480), Toxicol. Lett. 198 (2010) 134–143. doi:10.1016/j.toxlet.2010.06.011. 
[113] M.A. Cooperstein, H.E. Canavan, Assessment of cytotoxicity of (N-isopropyl 
acrylamide) and Poly(N-isopropyl acrylamide)-coated surfaces, Biointerphases. 8 (2013) 
19. doi:10.1186/1559-4106-8-19. 
[114] L.H. Lima, Y. Morales, T. Cabral, Ocular Biocompatibility of Poly-N-
Isopropylacrylamide (pNIPAM), J. Ophthalmol. (2016). doi:10.1155/2016/5356371. 
[115] A. Albanese, P.S. Tang, W.C.W. Chan, The Effect of Nanoparticle Size, Shape, and 
Surface Chemistry on Biological Systems, Annu. Rev. Biomed. Eng. 14 (2012) 1–16. 
doi:10.1146/annurev-bioeng-071811-150124. 
[116] Y. Porat, A. Abramowitz, E. Gazit, Inhibition of Amyloid Fibril Formation by 
Polyphenols: Structural Similarity and Aromatic Interactions as a Common Inhibition 
Mechanism, Chem. Biol. Drug Des. 67 (2006) 27–37. doi:10.1111/j.1747-
0285.2005.00318.x. 
[117] G. Forloni, L. Colombo, L. Girola, F. Tagliavini, M. Salmona, Anti-amyloidogenic 




[118] J. McLaurin, R. Cecal, M.E. Kierstead, X. Tian, A.L. Phinney, M. Manea, J.E. French, 
M.H.L. Lambermon, A.A. Darabie, M.E. Brown, C. Janus, M.A. Chishti, P. Horne, D. 
Westaway, P.E. Fraser, H.T.J. Mount, M. Przybylski, P.S. George-Hyslop, 
Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 
4–10 and inhibit cytotoxicity and fibrillogenesis, Nat. Med. 8 (2002) 1263–1269. 
doi:10.1038/nm790. 
[119] M. Fändrich, Oligomeric Intermediates in Amyloid Formation: Structure 
Determination and Mechanisms of Toxicity, J. Mol. Biol. 421 (2012) 427–440. 
doi:10.1016/j.jmb.2012.01.006. 
[120] C.G. Glabe, Common mechanisms of amyloid oligomer pathogenesis in degenerative 
disease, Neurobiol. Aging. 27 (2006) 570–575. 
doi:10.1016/j.neurobiolaging.2005.04.017. 
 
 
